The U.K. drug regulator has authorized Lilly’s Foundayo for use in weight management and in patients with type 2 diabetes, as noted in the column header. The source did not provide additional specifics about the authorization, such as the exact indications, dosing, label language, or the date the approval took effect. No further trial data, regulatory rationale, or implications for clinical practice were reported in the provided text.
Sanofi has alerted physicians and patient groups in both the United States and Europe that supplies of two medicines used to treat Pompe disease are diminishing. The affected products are Myozyme, an older standard-of-care enzyme-replacement therapy, and Nexviazyme, a newer treatment. According to the report, the company attributed the supply decline to a bottleneck in the final phase of manufacturing and to quality control concerns at its Waterford, Ireland facility.
The shortage notification came on the heels of a formal warning from the U.S. Food and Drug Administration (FDA) concerning manufacturing issues at that Irish plant. The source links this regulatory action with the timing of the supply problems but does not provide granular details such as the specific quality-control findings, the nature of the FDA warning, how long supplies are expected to be constrained, or concrete mitigation steps and timelines offered by Sanofi.
Patients and clinicians were informed of dwindling inventories, but the article did not report on inventory levels at treatment centers, prioritized allocation measures, alternative therapies, or guidance from professional societies. The reporting referenced STAT coverage of the shortage for additional context.
Jazz Pharmaceuticals has agreed to acquire Actio Biosciences in a deal reported to be worth up to $1.32 billion. The acquisition aims to add Actio’s experimental drug ABS-1230 to Jazz’s pipeline. ABS-1230 is being developed for KCNT1-related epilepsy, a severe inherited form of epilepsy that causes frequent seizures and developmental problems in children and for which there are currently no approved therapies, per the reporting.
Actio has estimated that the KCNT1-related epilepsy population in the United States is approximately 2,500 patients. Early pediatric data reportedly showed that ABS-1230 reduced seizures in children, and the agent is being studied in a trial intended to support a U.S. regulatory approval submission. The Reuters report cited in the source provided the transaction valuation and the strategic rationale but the provided text did not include further details about the trial design, magnitude of seizure reduction, safety findings, anticipated regulatory timelines, or financial terms beyond the headline valuation cap.
This edition of the Pharmalittle column by Ed Silverman (Aug. 10, 2026) summarized several distinct items of industry and regulatory news. Key items reported in full in the provided source include the Sanofi manufacturing and supply issue affecting Myozyme and Nexviazyme, and the Jazz Pharmaceuticals acquisition of Actio Biosciences to obtain ABS-1230 for KCNT1-related epilepsy. The U.K. authorization of Lilly’s Foundayo was listed in the heading, but the article text did not supply substantive details about that authorization.
Additional material referenced in the column was behind STAT’s subscription service (STAT+). Where the source did not report specifics — for example, precise FDA findings about the Waterford facility, expected duration of the Sanofi supply interruptions, detailed clinical trial results for ABS-1230, or the full terms and contingencies of the Jazz-Actio deal — those details were not available in the provided text and therefore are not included here.
Sources cited within the column include STAT reporting and a Reuters item for the Jazz-Actio acquisition. The rewritten summary preserves the factual content reported in the source and does not add information beyond what was published in the provided article excerpt.